Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

8 terminated/withdrawn out of 24 trials

Success Rate

63.6%

-22.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

7 of 14 completed trials have results

Key Signals

1 recruiting7 with results8 terminated

Enrollment Performance

Analytics

Phase 1

16(66.7%)

Early Phase 1

3(12.5%)

Phase 2

3(12.5%)

N/A

2(8.3%)

24Total

Phase 1(16)

Early Phase 1(3)

Phase 2(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (24)

Showing 20 of 24 trials

NCT05839912Not ApplicableRecruiting

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

Role: lead

NCT04116320Phase 1Terminated

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Role: lead

NCT04364230Phase 1Completed

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Role: lead

NCT02126579Phase 1Completed

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Role: lead

NCT03617328Phase 1Completed

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Role: lead

NCT02382549Early Phase 1Terminated

A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib

Role: lead

NCT02425306Phase 1Terminated

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

Role: lead

NCT02515227Phase 1Completed

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab

Role: lead

NCT00373217Phase 2Terminated

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Role: lead

NCT02305186Phase 1Unknown

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

Role: lead

NCT00118274Phase 1Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Role: lead

NCT01532960Phase 1Terminated

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

Role: lead

NCT02385669Phase 1Terminated

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

Role: lead

NCT00091286Early Phase 1Terminated

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Role: lead

NCT00118313Phase 1Completed

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Role: lead

NCT00912418Not ApplicableCompleted

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Role: lead

NCT00938223Phase 2Completed

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

Role: lead

NCT00977145Phase 1Terminated

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

Role: lead

NCT00892567Phase 1Completed

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer

Role: lead

NCT00705640Phase 1Completed

Vaccine Therapy in Treating Patients With Advanced Melanoma

Role: lead